Table 1.
Antibiotic | Case 1 | Case 2 | Case 3 | |||
---|---|---|---|---|---|---|
MIC (mg/L) |
Interpretation | MIC (mg/L) |
Interpretation | MIC (mg/L) |
Interpretation | |
Amikacin | >32 | R | - | - | - | - |
Aztreonam | >16 | R | ≤4 | S | ≤4 | S |
Cefepime | >16 | R | ≤2 | S | 8 | S |
Cefidericol | 8 | I | - | - | - | - |
Ceftazidime | >16 | R | ≤1 | S | 4 | S |
Ceftazidime/avibactam | >16 | R | - | - | - | - |
Ceftolozane/tazobactam | >8 | R | - | - | - | - |
Ciprofloxacin | >2 | R | ≤0.25 | S | >2 | R |
Delafloxacin | >2 | R | - | - | - | - |
Colistin | 2 | I | - | - | - | - |
Eravacycline | 4 | (ND) | - | - | - | - |
Gentamicin | >8 | R | ≤2 | S | >8 | R |
Imipenem | >16/4 | R | - | - | >8 | R |
Levofloxacin | >4 | R | ≤0.50 | S | >4 | R |
Meropenem | >8 | R | ≤1 | S | 2 | S |
Meropenem/vaborbactam | >16/8 | R | - | - | - | - |
Piperacillin/tazobactam | >64 | R | ≤8 | S | ≤8 | S |
Tobramycin | >8 | R | ≤2 | S | ≤2 | S |
Minimum inhibitory concentrations (MICs) were determined as per Clinical Laboratory Standards Institute (CLSI) guidelines in Mueller–Hinton broth. I, intermediate; ND, not determined; R, resistant; S, susceptible.